Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Arcus Biosciences (RCUS) has 6 years of Change in Accured Expenses data on record, last reported at $4.8 million in Q3 2022.

  • For Q3 2022, Change in Accured Expenses fell 74.69% year-over-year to $4.8 million; the TTM value through Sep 2022 reached $2.4 million, up 2572.53%, while the annual FY2021 figure was $8.4 million, 81.91% up from the prior year.
  • Change in Accured Expenses reached $4.8 million in Q3 2022 per RCUS's latest filing, down from $16.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $23.0 million in Q3 2020 and bottomed at -$19.1 million in Q4 2020.
  • Average Change in Accured Expenses over 5 years is $1.5 million, with a median of $1.4 million recorded in 2018.
  • Peak YoY movement for Change in Accured Expenses: crashed 22337.5% in 2018, then skyrocketed 547.27% in 2020.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.8 million in 2018, then crashed by 259.26% to -$2.9 million in 2019, then plummeted by 550.48% to -$19.1 million in 2020, then skyrocketed by 43.33% to -$10.8 million in 2021, then surged by 144.49% to $4.8 million in 2022.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $4.8 million in Q3 2022, $16.9 million in Q2 2022, and -$8.5 million in Q1 2022.